A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023) (MOVe-NOW)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 3

Conditions: Coronavirus Disease (COVID-19)

Treatments: Drug: Placebo; Drug: Molnupiravir

Study type: Interventional

Funder types: Industry

Identifiers

NCT06667700

U1111-1295-4678 (Other Identifier)

MK-4482-023 (Other Identifier)

2023-507227-36 (Registry Identifier)

4482-023

Details and patient eligibility

About

Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms. However, people with certain health conditions or other factors have a high risk (chance) of getting severely ill from COVID-19, which can require a hospital stay or lead to death. Some people who are high risk for severe illness may be unable to take certain treatments for COVID-19 because they are not available to them, or they take other medicines that may react with a treatment and cause an unwanted effect.

Molnupiravir (MK-4482) is a study medicine designed to stop the COVID-19 virus from copying itself in the body (multiplying). The goal of this study is to learn if molnupiravir prevents severe illness from COVID-19 more than placebo in people who are high risk.

Enrollment: 3,082 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

• Is an individual of any sex/gender, ≥18 years of age

• Has documentation of SARS-CoV-2 infection with sample collection ≤4 days prior to randomization

• Has initial onset of signs/symptoms attributable to COVID-19 for ≤4 days prior to the day of randomization and ≥2 of the following signs/symptoms attributable to COVID-19 on the day of randomization: cough, sore throat, nasal congestion, shortness of breath or difficulty breathing with exertion, muscle or body aches, fatigue, fever >38.0°C or chills, nausea or vomiting or diarrhea, change in sense of smell or change in sense of taste, or headache

• Has ≥1 of the following characteristics or medical conditions associated with the highest risk of severe illness from COVID-19:

  • Advanced age of ≥75 years of age
  • Immunocompromised
  • Neurocognitive or physical disability

• Has ≥3 characteristics or medical conditions which increase the risk of severe illness due to COVID-19 (e.g., chronic lung disease, obesity with body mass index ≥35, diabetes)

• Is unable to receive treatment with nirmatrelvir/ritonavir (NMV/r) due to 1 or more of the following:

  • Is receiving drug(s) highly dependent on cytochrome P450 3A (CYP3A) for clearance and for which elevated concentrations are associated with serious and/or life-threatening consequences or drug(s) with a clinically significant drug-drug interaction for which co-administration is not possible
  • Is receiving potent CYP3A inducers where significantly reduced nirmatrelvir or ritonavir plasma concentrations may be associated with the potential for loss of virologic response and possible resistance
  • Has severe renal or hepatic impairment
  • Has experienced prior adverse reactions or hepatotoxicity to NMV/r that would preclude future use
  • Has uncontrolled HIV infection
  • Has known or suspected NMV/r resistance
  • NMV/r is not approved/authorized in the participant's country or it is not accessible to participant (e.g., drug shortage)

Inclusion note: Participants may receive remdesivir as standard of care in addition to molnupiravir or placebo. If remdesivir is available and clinically appropriate per local clinical practice, investigators will aim to ensure that those who are most vulnerable to severe COVID-19 receive timely access to remdesivir as standard of care on this study.

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

• Is currently hospitalized or is expected to need hospitalization for COVID-19 imminently

• Has received or plans to receive SARS-CoV-2 directed antivirals or monoclonal antibodies for current episode of COVID-19 (other than study intervention and, if applicable, remdesivir as standard of care)

• Has ≥1 of the following signs/symptoms that are attributable to severe or critical COVID-19:

  • Shortness of breath at rest
  • Respiratory rate ≥30 breaths per minute
  • Heart rate ≥125 beats per minute
  • Peripheral oxygen saturation (SpO2) ≤93% on room air or on supplemental oxygen for a reason other than COVID-19 which has not increased since onset of COVID-19 signs/symptoms
  • Is receiving >4 liters/minute supplemental oxygen for COVID-19 (but was not receiving supplemental oxygen prior to COVID-19), regardless of SpO2

• Has received a COVID-19 vaccine within 30 days prior to randomization

• Has a history of SARS-CoV-2 infection (with or without symptoms) within 30 days prior to randomization

• Has known or suspected hypersensitivity to active or inactive ingredients of molnupiravir

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

3,082 participants in 2 patient groups, including a placebo group

Molnupiravir

Experimental group

Description:

Participants will receive 800 mg molnupiravir orally every 12 hours for 5 days (a total of 10 consecutive doses)

Treatment:

Drug: Molnupiravir

Placebo

Placebo Comparator group

Description:

Participants will receive molnupiravir-matching placebo orally every 12 hours for 5 days (a total of 10 consecutive doses)

Treatment:

Drug: Placebo